Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity

• Status: Withdrawn
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

The proposed study is a prospective cohort study incorporating patients with first recurrence ovarian or primary peritoneal cancer who will receive intraperitoneal chemotherapy in conjunction with whole abdomen radiation. The primary end point of this investigator initiated research study is to determine the toxicity associated with whole abdomen radiation in combination with intraperitoneal chemotherapy.

Primary Objective:

• Determine the maximum tolerated dose (MTD) of whole abdomen radiation in conjunction with intraperitoneal cisplatin chemotherapy in the treatment of women with small volume (< 1 cm) recurrent ovarian cancer confined to the abdominal peritoneal cavity.

Secondary Objective:

• Quality of Life assessment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

1. Recurrent ovarian cancer or primary peritoneal cancer with disease confined to the abdomen and pelvis, who have undergone optimal cytoreductive surgery for recurrence

2. Must have received only one prior chemotherapeutic regimen as their prior therapy

3. Eligible patients must have received platinum based intravenous chemotherapy as their only prior therapy. Previous treatment with maintenance chemotherapy after initial adjuvant chemotherapy is acceptable, including anti-estrogen therapy and growth factors. Previous intraperitoneal chemotherapy is not allowed

4. Patients have evidence of recurrent cancer manifested by either a) elevation in serum CA-125 or a palpable tumor on physical exam and/or b) radiographic evidence of recurrence. (Note that a tissue biopsy for histologic confirmation of tumor recurrence prior to cytoreductive surgery is not necessary, however histologic confirmation of the removed tumor is necessary- see exclusion 5.22)

5. Tumors with serous, mucinous, clear cell, or endometrioid histologic types are eligible

6. Recurrent disease must be confined to the abdominal cavity

7. Recurrence of tumor must be greater than six months from completion of primary chemotherapy (platinum sensitive ovarian cancer)

8. Patients have undergone a second cytoreductive surgery to remove all gross residual disease. This cytoreductive surgery must occur within twelve weeks of enrollment

9. Patients have or are planning to have an IP catheter

10. Patients who require rectosigmoid resection with primary anastamosis will be eligible

11. Adequate renal function as defined by serum creatinine less 2.0mg/dL

12. Patients must have appropriate hematologic parameters with total white blood cell (WBC) counts ≥ 3,000cells/mcl and platelet counts ≥ 100,000/mcl prior to treatment initiation

13. Patients must have the absence of pleural effusions on chest radiographs

14. Patients must sign informed consent approved by the University of Utah and institutional review board (IRB)

15. ECOG performance status less than or equal to 2

16. Age greater than 18 years old

Exclusion Criteria:

1. Patients previously characterized with stage IV disease or those with stage IIIC who underwent suboptimal secondary cytoreductive surgery for recurrence will not be eligible for participation

2. Patients who undergo secondary cytoreductive surgery for recurrence and have no recurrent disease by histologic documentation will not be eligible

3. Those with preoperative evaluation consistent with stage IV disease (pleural effusion or liver parenchymal disease)

4. Patients with disease outside the peritoneal cavity including disease in the thorax, within the parenchyma of the liver, spleen, or retroperitoneal nodal disease will not be eligible for participation

5. Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy

6. Patients determined to have platinum resistant ovarian or primary peritoneal cancer

7. Those who had suboptimal cytoreductive surgery at the time of first diagnosis. This includes patients who had a suboptimal cytoreductive surgery followed by chemotherapy, then a secondary debulking and now have a recurrence

8. Those with > 1cm residual disease after the second cytoreductive surgery

9. Patients that have been treated with previous intraperitoneal chemotherapy

10. Patients that are pregnant or lactating

11. Patients with peripheral neuropathy greater than grade 2 at baseline